
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences demonstrates a positive financial outlook driven by the anticipated approval and launch of Trodelvy in the second half of 2026, which is expected to strengthen and diversify its oncology pipeline while achieving a 90% payer coverage goal ahead of schedule. The company is poised for substantial revenue growth, with Livdelzi projected to exceed $1 billion in peak revenue and strong sales momentum observed in its HIV franchise, with a 6% year-over-year growth forecasted for 2026. Additionally, Gilead's operational discipline and improving operating margins, alongside robust expansion in the HIV PrEP market, further support the company's favorable financial trajectory.
Bears say
Gilead Sciences has adjusted its revenue forecasts downward significantly, anticipating a decline in Veklury revenues from $1.4 billion to $1.0 billion for FY25, and projecting further reductions to $600 million by 2026, indicating a troubling trend. The cell therapy segment, which reported $458 million in revenue but saw a 6% year-over-year decrease, is expected to face ongoing competitive pressures, with guidance suggesting a 10% revenue decline in 2026. Overall, the company faces a combination of policy-related headwinds and competitive dynamics that could lead to a continued downturn in key revenue streams, further negatively impacting its financial outlook.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares